as well as look at the competition, both from a scientific standpoint as well as on their financing structure (in case one or two might look more interesting)
TLR 7/9 http://www.dynavax.com <- well, according to a reuters article they will either have outlicensed their HCB vaccine soon or need some kind of (probably?) debt financing to commercialize it & finance their IO-program http://checkmatepharma.com <- private company http://www.iderapharma.com <- have not checked financing structure yet http://www.mologen.com <- personally, I really do not like their financing structure
(certainly not a complete list, but these should be the more known ones)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.